Discover a world of educational opportunities to support your lifelong learning
RACGP offer courses and events to further develop the knowledge you need to develop your GP career
2022 RACGP curriculum and syllabus
for Australian general practice
The Abuse and violence: working with our patients in general practice provides the best-available current evidence for GPs
Stay up-to-date with the latest information and resources on the COVID-19 vaccine rollout.
Download the Standards for general practice (5th edition) - a benchmark for quality care and risk management in Australian general practices
Coronavirus (COVID-19) resources for general practitioners
Advice and guidelines for GPs and practice teams to help protect general practice information systems
Video consultations can provide convenient and accessible healthcare delivery
Read all of the RACGP reports and submissions on various healthcare topics
Read all of the RACGP position statements on various healthcare topics
Join our RACGP Facebook groups
Genomics in general practice
Disease specific topics
General practitioners (GPs) are well placed to undertake opportunistic screening for familial hypercholesterolaemia (FH). Family screening is critical when a diagnosis of FH is made in an individual.
FH is a lipid disorder that leads to premature cardiovascular disease (CVD). FH most often follows an autosomal dominant inheritance When a condition follows an autosomal dominant pattern of inheritance, the family tree will usually reveal multiple affected members in multiple generations on the same side of the family. Dominant conditions or traits are expressed when only a single is inherited. Wide variability in clinical expression is common in many autosomal dominant conditions, even within the same family. Early onset of conditions, such as cancer, can be indicative of autosomal dominant inheritance within a family. Not all dominant conditions show 100% penetrance (eg BRCA1 gene mutations). pattern. If FH is left untreated, males have a 50% chance of developing CVD before 50 years of age, and women have a 30% chance of developing CVD by 60 years of age. Early diagnosis and treatment of FH reduces the risk of CVD.
The risk of FH can be assessed using the Dutch Lipid Clinic Network Criteria (DLCNC).
FH assessment should be conducted when an individual presents with:
While FH can be diagnosed clinically, a confirmatory DNA test allows for cascade screening Cascade screening involves testing the close biological relatives of an individual who has or is a carrier of a genetic condition in order to determine whether these relatives carry the genetic variant or chromosomal alternation (thereby increasing their chances of developing the condition or having a child with the condition). For example, cascade testing is available under the Medicare Benefits Schedule for genetic testing for familial hypercholesterolaemia. within the family of an affected patient. There is MBS funding for genetic testing for FH. MBS item 73352 can only be ordered by specialist physician to make the diagnosis; GPs can order the test for cascade screening.
Refer individuals with a DLCNC score of ≥3 (ie possible-to-definite FH) to a cardiologist or lipid clinic for confirmation of diagnosis, including possible genetic testing.
Those diagnosed with FH should be encouraged to:
Did you know you can now log your CPD with a click of a button?